trialport

Find your trial

Refractory hypercholesterolemia: a plain-language guide

trialport plain-language guide to Refractory Hypercholesterolemia
Keith

Refractory hypercholesterolemia is not a separate disease: it is the situation where LDL cholesterol stays above the level a doctor is aiming for, even though the person already takes the strongest cholesterol-lowering treatment they can manage [2].

This page provides general information. It does not replace advice from a doctor or another qualified healthcare professional.

Key facts

  • Refractory hypercholesterolemia describes cholesterol that stays above target despite the highest tolerated dose of cholesterol-lowering treatment. It describes a situation, not a diagnosis in its own right [2].
  • High cholesterol usually causes no symptoms at all. Most people only find out from a blood test [6,9].
  • It is most common in people who started with very high cholesterol, especially those with the inherited condition familial hypercholesterolemia, which affects an estimated 1 in 200 to 1 in 250 people in most countries [2,10].
  • Muscle aches blamed on statins are genuinely felt, though two carefully designed studies found most of that symptom burden also appeared on placebo tablets [16,17].
  • Options beyond statins include ezetimibe, bempedoic acid, PCSK9 inhibitors, inclisiran and lipoprotein apheresis. What is funded and available differs between countries [1,5,7,15].
  • There is no reliable worldwide figure for how many people are affected, though evidence from treatment studies suggests the number is larger than once assumed [2].

On this page

What is refractory hypercholesterolemia?

Cholesterol is a waxy, fat-like substance the body needs to build cell walls, make hormones and digest fat [10]. Low-density lipoprotein, or LDL, carries it in the blood and leaves it in artery walls, forming patches called plaques that narrow arteries and raise the risk of a heart attack or stroke [1,10].

“Refractory” means a problem keeps resisting treatment. Doctors use the phrase when a clear LDL cholesterol goal exists, the person already takes the most cholesterol-lowering medicine they can tolerate, and the number is still above that goal [2]. The 2026 United States guideline sets that goal below 100, 70 or 55 mg/dL as risk rises, and England aims for 2.0 mmol per litre or less after a cardiovascular event [1,5].

Names that get mixed up. Hypercholesterolemia means too much cholesterol in the blood [11]. Hyperlipidemia is wider, covering raised cholesterol and raised triglycerides, and dyslipidemia wider still, meaning any unhealthy pattern of blood fats [1]. Work on treatment resistance concerns LDL cholesterol, so the narrower term is the accurate one [2].

How common is it?

Reliable figures are not available. No agreed way of counting exists, and no dedicated guideline defines the situation [2].

Failing to reach target is common, though. Roughly 1 in 4 adults in the United States has a high LDL cholesterol level to begin with [1], and among people with familial hypercholesterolemia taking a PCSK9 inhibitor on top of usual treatment, 30 to 40 percent still did not get below 70 mg/dL [2]. That figure comes from clinical studies, so everyday practice probably looks worse.

What causes it?

Two questions sit inside this one. Why was the cholesterol so high to begin with, and why is treatment not bringing it down far enough.

Inherited causes. Genes are the instructions inside our cells. Familial hypercholesterolemia is caused by a change in one of a small group of genes, most often LDLR [10]. That gene makes the LDL receptor, a structure on liver cells that pulls LDL cholesterol out of the blood, so with fewer working receptors cholesterol builds up. It is passed on in an autosomal dominant pattern, meaning one changed copy is enough, so each child of an affected parent has a one in two chance of inheriting it [11].

Lipoprotein(a). This separate cholesterol-carrying particle is set almost entirely by inherited factors and stays steady for life. A level of 125 nmol/L or above carries roughly 1.4 times the long-term risk of heart attack or stroke, and everyday cholesterol medicines barely change it [1].

Other conditions and medicines. Cholesterol can be raised by an underactive thyroid, chronic kidney disease, diabetes, lupus, HIV, sleep apnea and extra weight, and by medicines including amiodarone and beta-blockers [8]. These are called secondary causes, and doctors look for them before deciding treatment has failed [5,8].

Why treatment falls short. Statins work by prompting liver cells to make more LDL receptors, so where very few receptors work at all the response is weak by design [2].

What are the symptoms?

There are usually none, and this is precisely why the condition often goes untreated for years. High LDL cholesterol does not hurt and does not make a person feel unwell. Most people learn about it only from a blood test taken for another reason [6,9].

Where cholesterol is very high there are sometimes visible signs, including fatty yellowish bumps called xanthomas over tendons and a grey ring at the edge of the cornea [9,10]. These point toward familial hypercholesterolemia rather than treatment failure, and many people have none of them.

When to seek urgent help. The condition itself is not an emergency. What it raises is the chance of a heart attack or stroke, and those are [1]. Call emergency services immediately for chest discomfort lasting more than a few minutes, pain spreading to the arms, back, neck or jaw, or shortness of breath, and for a drooping face, weakness in one arm or slurred speech, even if the symptoms pass [18].

How is it diagnosed?

A blood test called a lipid panel measures total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides. Since there are no symptoms, testing is the only way to know [6,9]. Screening is now advised for all children aged 9 to 11 who have not been tested [1].

Calling something refractory takes several steps rather than one test. Guidance for clinicians is to check whether doses are being taken and when, look for other conditions and medicines that raise cholesterol, and increase the statin dose where the person is not yet on the maximum they can tolerate [5]. Only then does the label make sense.

Lipoprotein(a) should be measured at least once in adult life, and since the level barely moves, repeat testing is generally unnecessary [1]. Referral to a lipid clinic, a specialist center for abnormal blood fats, is common where levels will not come down [14].

How is it treated?

There is no cure. Treatment is lifelong and aims to bring LDL cholesterol down as far as a person’s risk level requires. Statins remain the foundation everywhere [1,6,7], and at high intensity and maximum dose can lower LDL cholesterol by about 50 to 60 percent [2]. Where that is not enough, the usual order is to add ezetimibe, then a PCSK9 inhibitor [3].

Statin intolerance, honestly. Muscle aches, stiffness and weakness are the usual reasons people stop statins, and may affect around 10 to 15 percent of users [2]. Two studies tested this properly. StatinWISE gave 200 people who had previously reported severe muscle symptoms atorvastatin or a matching placebo across six two-month periods without telling them which was which, and found no evidence of a difference in symptom scores between statin and placebo periods [16]. SAMSON gave 60 people atorvastatin, placebo and no tablets in random order. Scores were much lower in the no-tablet months than in the statin or placebo months, which were similar, and about 90 percent of the symptom burden on the statin also appeared on placebo. Six months later, half had restarted a statin [17]. The symptoms are real. Much of the burden appears to come from taking a tablet rather than from the medicine inside it, so a careful second try is worth discussing. NICE advises stopping and restarting, lowering the dose, or switching statin before concluding someone cannot tolerate statins at all [5].

Other options. Ezetimibe reduces how much cholesterol the gut absorbs [1,5,7]. Bempedoic acid lowers LDL cholesterol by roughly 17 to 28 percent and is often chosen where statins are not tolerated, with gout and gallstones as recognized side effects [2]. Alirocumab and evolocumab, injections that block a protein called PCSK9, lower it by around 59 percent, and inclisiran works on the same protein twice a year, lowering it by around half [2]. Inclisiran is an option in England [5,7], though the 2026 United States guideline notes that whether its cholesterol lowering means fewer heart attacks and strokes is still being studied [1].

Lipoprotein apheresis. Blood is drawn, passed through a column that removes LDL cholesterol, and returned to the body. One treatment lowers LDL cholesterol by 50 to 65 percent and also removes lipoprotein(a), though the effect does not last, so it is repeated every one or two weeks indefinitely [15]. Few centers offer it. Which medicines are funded, and after which other treatments, is decided country by country [1,5].

Living with refractory hypercholesterolemia

This is a long-term situation rather than an illness with an end point, and most of daily life is unaffected. Treatment continues indefinitely, with blood tests to check progress. Lifestyle still counts even when it is not enough alone: guidance emphasizes a healthy weight, regular activity, avoiding tobacco and good sleep alongside medicine, and most cholesterol-lowering treatments are paused when trying to conceive, during pregnancy and while breastfeeding [1].

Where an inherited cause is found, relatives can be offered testing, since a child of a parent with familial hypercholesterolemia has a one in two chance of having it [11]. Keeping a record of which statins have been tried and what happened is useful. The emotional side is real too: watching the number stay high can feel discouraging, and it is easy to read that as personal failure when it is usually biology.

Thinking about a clinical trial?

Clinical trials are research studies that test whether a treatment or approach works and is safe. Cholesterol lowering is an active research area, so studies come up reasonably often. Deciding whether to look into one is a personal choice, and it helps to take it in steps.

1. Understand what the study is asking

It is worth being clear on:

  • what the researchers are trying to learn
  • what is being studied, and what it is compared with
  • how long the study lasts
  • what visits, tests or procedures are involved, and how often
  • whether travel is required, and how far
  • the possible benefits, and the known and unknown risks
  • what happens when the study ends, including whether treatment continues

2. Consider possible medical suitability

Every trial has rules about who can take part, called eligibility criteria. For a study in this area, they might include an LDL cholesterol level above a stated number on a recent blood test, a stable dose of statin and ezetimibe for a set number of weeks beforehand, a confirmed genetic diagnosis, whether a person already receives a PCSK9 inhibitor, inclisiran or apheresis, or a recent heart attack or stroke.

trialport’s medifit helps people consider information related to possible medical suitability. It does not diagnose a condition, confirm eligibility or replace formal screening by the study team.

Explore refractory hypercholesterolemia clinical trials through trialport

3. Consider whether participation fits your life

A study can look like a good match on paper and still be hard in practice. Worth thinking through:

  • the time each visit takes, and how many visits there are
  • travel, distance and who would come along
  • work, school or caring responsibilities
  • support from family and friends
  • how you feel about injections or repeated blood tests
  • whether stopping or changing a current medicine would be required
  • whether it feels right to you, separate from what anyone else thinks

trialport’s readifit helps people reflect on their understanding, motivation, time, routines, support, emotions and practical arrangements.

4. Ask questions before deciding

Useful questions to put to a research team:

  • Why is this study being carried out, and what is already known?
  • What exactly would I need to do, and for how long?
  • What are the known risks, and what is still unknown?
  • Would I need to stop or change any medicine I take now?
  • Could I receive a placebo? A placebo is a dummy treatment with no active medicine, used so researchers can compare results fairly.
  • Can I leave the study after joining, and what happens if I do?
  • Who provides my usual medical care, and who do I contact if I feel unwell?
  • Are travel and other costs covered?
  • What happens after the study ends, and could I keep receiving the treatment?
  • Will I be told the results?

Taking part is voluntary. A person can ask questions, speak with people they trust and choose not to participate.

Search for clinical trials at app.trialport.com.

Current research

Study status checked: 3 August 2026. Research moves, and what is being studied changes, so this describes broad areas rather than a fixed list.

  • Gene-based approaches. Gene editing has been used to switch off PCSK9 in the liver, with reductions of up to about 55 percent in early human work, alongside temporary infusion reactions and short-lived rises in liver blood tests. None of this is approved treatment [2].
  • Routes that do not need the LDL receptor. Blocking a protein called ANGPTL3 lowers cholesterol without working LDL receptors. Evinacumab, an antibody against it, was added to European guidance in 2025 for the severe inherited form [2,4].
  • Lowering lipoprotein(a). Several treatments aimed at reducing it are in trials [2,4].

Where you want current trial information, search at app.trialport.com.

Support and further information

In the United Kingdom, HEART UK is the cholesterol charity and explains inherited high cholesterol in plain terms [11]. Its lipid clinic finder is the most practical tool here for anyone whose cholesterol will not come down [14]. The NHS pages on high cholesterol cover testing, lifestyle and medicines clearly [6,7].

In the United States, the Family Heart Foundation focuses on inherited high cholesterol and raised lipoprotein(a) [12], the National Heart, Lung, and Blood Institute sets out causes and risk factors accessibly [8,9], and MedlinePlus Genetics is reliable on the genetics [10]. Across Europe, the European Atherosclerosis Society publishes the guidance clinicians follow [4,13].

Coverage elsewhere is thinner, and dedicated organizations are uncommon in Australia, New Zealand, Asia, the Middle East, Africa and South America. Where no local group exists, a hospital lipid clinic or a national heart charity is the best first contact.

Questions people often ask

Is refractory hypercholesterolemia a disease?
No. It describes a situation, where cholesterol stays above target despite the strongest treatment a person can tolerate [2]. The underlying cause, often an inherited condition, is the actual diagnosis.

Is it the same as refractory hyperlipidemia?
Not quite. Hyperlipidemia is broader and includes raised triglycerides as well as raised cholesterol [1,11]. Work on treatment resistance almost always concerns LDL cholesterol, so hypercholesterolemia is the more accurate name [2].

If I got muscle aches on a statin, can I never take one?
Not necessarily. The symptoms are genuinely felt, and two well-designed studies found most of the symptom burden also occurred on placebo tablets, with half the participants in one restarting a statin afterward [16,17]. A careful second try, or a different statin or dose, is worth discussing with a doctor [5].

Should my children be tested?
Possibly. Screening is advised for all children aged 9 to 11 who have not been tested [1], and where a parent has familial hypercholesterolemia each child has a one in two chance of having inherited it [11].

Why is my target number different from someone else’s?
Targets depend on overall risk and on national guidance, and countries use different units [1,5].

Sources

  1. American College of Cardiology and American Heart Association. ACC/American Heart Association Issue Updated Guideline for Managing Lipids, Cholesterol (announcing the 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia). 13 March 2026. https://newsroom.heart.org/news/accaha-issue-updated-guideline-for-managing-lipids-cholesterol Accessed 3 August 2026.
  2. Pawlos A, Khoury E, Gaudet D. Emerging therapies for refractory hypercholesterolemia: a narrative review. Future Cardiology. 2024;20(5-6):317. https://doi.org/10.1080/14796678.2024.2367860 (PMID 38985520). Accessed 3 August 2026.
  3. Rubenfire M. 2019 ESC/EAS Guidelines for Management of Dyslipidemias: ten points to remember. American College of Cardiology. 12 September 2019. https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2019/09/12/15/13/2019-ESC-EAS-Guidelines-for-Dyslipidaemias Accessed 3 August 2026.
  4. European Atherosclerosis Society. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias: summary of new recommendations. 2025. https://eas-society.org/publications/guidelines/2025-focused-update-of-the-2019-esc-eas-guidelines-for-the-management-of-dyslipidaemias/ Accessed 3 August 2026.
  5. National Institute for Health and Care Excellence. Cardiovascular disease: risk reduction, including lipid modification. NICE guideline NG238, recommendations. December 2023. https://www.nice.org.uk/guidance/ng238/chapter/Recommendations Accessed 3 August 2026.
  6. NHS. High cholesterol: what is high cholesterol? Reviewed 13 March 2026. https://www.nhs.uk/conditions/high-cholesterol/ Accessed 3 August 2026.
  7. NHS. High cholesterol: medicines for high cholesterol. Reviewed 13 March 2026. https://www.nhs.uk/conditions/high-cholesterol/medicines-for-high-cholesterol/ Accessed 3 August 2026.
  8. National Heart, Lung, and Blood Institute. Blood cholesterol: causes and risk factors. https://www.nhlbi.nih.gov/health/blood-cholesterol/causes Accessed 3 August 2026.
  9. National Heart, Lung, and Blood Institute. Blood cholesterol: symptoms. https://www.nhlbi.nih.gov/health/blood-cholesterol/symptoms Accessed 3 August 2026.
  10. MedlinePlus Genetics, National Library of Medicine. Familial hypercholesterolemia. https://medlineplus.gov/genetics/condition/familial-hypercholesterolemia/ Accessed 3 August 2026.
  11. HEART UK. What is FH? (genetic high cholesterol). https://www.heartuk.org.uk/cholesterol/what-is-fh Accessed 3 August 2026.
  12. Family Heart Foundation. https://familyheart.org/ Accessed 3 August 2026.
  13. European Atherosclerosis Society. https://eas-society.org/ Accessed 3 August 2026.
  14. HEART UK. Find your nearest cholesterol specialist. https://www.heartuk.org.uk/lipid-clinics/find-your-nearest-lipid-clinic Accessed 3 August 2026.
  15. Royal Brompton and Harefield hospitals. Lipoprotein apheresis. https://www.rbht.nhs.uk/our-services/lipoprotein-apheresis Accessed 3 August 2026.
  16. Herrett E, Williamson E, Brack K, et al. The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTs. Health Technol Assess. 2021;25(16). https://doi.org/10.3310/hta25160 Accessed 3 August 2026.
  17. O’Riordan M. Both statins and placebos produce ‘very real’ side effects: SAMSON. TCTMD, Cardiovascular Research Foundation. 15 November 2020. https://www.tctmd.com/news/both-statins-and-placebos-produce-very-real-side-effects-samson Accessed 3 August 2026.
  18. American Heart Association. Heart attack, stroke and cardiac arrest symptoms. https://www.heart.org/en/about-us/heart-attack-and-stroke-symptoms Accessed 3 August 2026.

Review information

Written by: trialport editorial team
Reviewed by: Keith Berelowitz, Founder and CEO, trialport
Reviewed on: 3 August 2026
Next review due: 3 August 2027
References last checked: 3 August 2026